Maintenance treatment in metastatic colorectal cancer

In CAIRO3, the poor prognostic group of patients with disease progression before completion of induction treatment were excluded, as were the probably larger group of patients with a good prognosis in whom resection of metastases was either planned or likely to be achieved. [...]the study population...

Full description

Saved in:

Bibliographic Details
Published in:	The lancet oncology Vol. 16; no. 16; pp. e582 - e583
Main Authors:	Simkens, Lieke H J, van Tinteren, Harm, Punt, Cornelis J A, Koopman, Miriam
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01-12-2015 Elsevier Limited
Subjects:	Angiogenesis Inhibitors - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab - therapeutic use Capecitabine - therapeutic use Colorectal cancer Colorectal Neoplasms - drug therapy Female Fluorouracil - therapeutic use Hematology, Oncology and Palliative Medicine Humans Leucovorin - therapeutic use Maintenance Chemotherapy Male Medical prognosis Metastasis Organoplatinum Compounds - therapeutic use
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In CAIRO3, the poor prognostic group of patients with disease progression before completion of induction treatment were excluded, as were the probably larger group of patients with a good prognosis in whom resection of metastases was either planned or likely to be achieved. [...]the study population of CAIRO3 is a subset of patients with metastatic colorectal cancer and cannot be directly compared with other trials. [...]Hegewisch-Becker and colleagues mention that CAIRO3 does not have information about censoring of patients.
Bibliography:	SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1 ObjectType-Commentary-2 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1470-2045 1474-5488
DOI:	10.1016/S1470-2045(15)00374-5